FDA Approves ConcizuTrace™ ELISA Companion Diagnostic for 2024 Concizumab Therapy in Hemophilia
The National Bleeding Disorders Foundation (NBDF) shared a post on X:
”The FDA has approved the ConcizuTrace™ ELISA Companion Diagnostic test to measure concizumab-mtci levels in hemophilia A and B patients.’
To learn more about this advancement, follow the link.
The U.S. Food and Drug Administration (FDA) has approved the ConcizuTrace™ ELISA Companion Diagnostic, a test designed to measure plasma levels of concizumab-mtci in patients with hemophilia A or B.
Concizumab-mtci is a subcutaneous therapy indicated for routine prophylaxis to prevent or reduce bleeding episodes in adult and pediatric patients (≥12 years) with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors.
The approval of this companion diagnostic marks a significant step in personalizing treatment, enabling clinicians to monitor drug exposure and potentially optimize therapeutic outcomes.
Never miss the important in the World of Hemophilia, read Hemostasis Today.
-
Apr 12, 2026, 12:04Riccardo Fumagalli: Long Term Complications Following Catheter Directed Thrombolysis in PE
-
Apr 12, 2026, 11:36Ifeanyichukwu Ifechidere: From Running Tests to Trusting Interpretation in Coagulation
-
Apr 12, 2026, 11:30Zack Rosanova: What Happens to Your Brain Without Sleep
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be